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Introduction 
In April 1994, the Regional Respiratory Medical 
Group based at University Medicine, Southampton 
General Hospital, U.K. hosted a national meeting 
reviewing a range of important areas in contempo- 
rary asthma research. In the words of Stephen 
Holgate, who opened the meeting, the aim was to 
explore the ‘frontiers of asthma research’. 
The Early Life Origins of Asthma 
The first half of the meeting was devoted to the 
early life origins of asthma and opened with an ad- 
dress from Michael Silverman (Paediatric Respiratory 
Medicine at the Royal Postgraduate Medical School, 
London, U.K.). There are problems with the proper 
definition of early asthma in childhood, and the con- 
cepts of asthma which have been derived from clinical 
and epidemiological work on school children and 
young adults cannot be applied to pre-school children. 
If one sticks to a definition of asthma as a. chronic 
inflammatory condition in which heightened bron- 
chial responsiveness is associated with recurrent, 
reversible airway obstruction, then the syndrome of 
asthma cannot be shown to exist in this age group. 
There is no evidence concerning the nature or per- 
sistence of an inflammatory process in the airways of 
wheezy young children. There is also no evidence to 
support a greater degree of bronchial responsiveness 
in wheezy infants (or in any wheezy children up to 
the age of 7 years) compared with their non-wheezy 
counterparts. Finally, there are few, if any, data on the 
variability of airway obstruction with time in children 
with wheezing conditions under 5 years of age. 
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Wheezy infants 
Infants with recurrent 
episodic wheezing in 
association with URTI. 
No association with 
atopy or increased IgE 
factors. Raised 
Fig. I The range of wheezing illness in infancy and child- 
hood. There are two main groups with considerable overlap. 
Currently there is no evidence for either bronchial hyper- 
responsiveness or airways inflammation in infancy. URTI, 
upper respiratory tract infection. 
There is considerable evidence to suggest that at 
least two asthma-like syndromes exist in the earliest 
years (Fig. 1). One consists of recurrent episodic 
wheezing associated with viral respiratory tract infec- 
tions, typically with symptom-free intervals, and with 
no significant association with atopy or IgE produc- 
tion. This is a relatively self-limiting disorder which 
seems to improve with age, although it may persist in 
a mild form in adults and has not been adequately 
investigated. The other syndrome is ‘typical’ child- 
hood asthma in which wheezing occurs in response to 
numerous triggers usually on an allergic basis. This is 
less common in the first year of life but seems to 
become more common towards school age. The 
decline of the former, and the increase of the 
latter variety of asthma results in a fairly constant 
prevalence of wheezing disorders during childhood. 
The foetal origins of asthma were suggested to 
have, at least in part, an anatomical pulmonary basis 
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(Keith Godfrey, MRC Environmental Epidemiology 
Unit, Southampton, U.K.) and a contribution due to 
foetal sensitization or priming of the foetal immuno- 
logical system by maternal factors (John Warner, 
Child Health, Southampton). The importance of 
viruses as provokers of asthma episodes in childhood 
was emphasized by Steven Myint (Leicester, U.K.). 
Studies performed in Southampton and Leicester 
have shown that over 80% of acute wheezing attacks 
in children are associated with a respiratory viral 
infection. In both cohorts of children, rhinovirus was 
the most frequent pathogen, responsible for more 
than 50% of exacerbations. The exception to this was 
in children aged 2 years or less where respiratory 
syncytial virus was the predominant virus identified. 
In spite of our lack of understanding of the histo- 
logical changes in the airways of children, there has 
been a belief that children with infrequent, mild 
episodes of wheezing provoked by viral infections 
need only intermittent treatment with bronchodilator 
drugs. There is every reason to believe that the 
chronic inflammatory changes seen in adults with 
asthma develop in childhood and this is beginning to 
affect drug treatment of childhood asthma. This area 
was discussed by John Price (Kings College Hospital, 
London) with reference to the increasing use of 
national and international guidelines. Sodium cromo- 
glycate remains the first line preventive agent for 
children with moderate asthma, but its mode of 
action remains unclear. When control is inadequate, 
when it is not possible to give a drug four times daily 
or when asthma is more severe, then inhaled corticos- 
teroids should be used. The adverse effects of inhaled 
corticosteroids remain difficult to assess. Inhaled 
corticosteroids in high doses, particularly when given 
as a powder inhaler, can cause growth deceleration 
but have not been shown to affect final height. Poor 
asthma control can have an adverse effect on growth. 
There is some evidence that in high doses, budesonide 
has less effect on the hypothalamus-pituitary- 
adrenal axis than beclomethasone, while fluticasone 
has lower oral bioavailability than either budesonide 
or beclomethasone. Theophylline use should now be 
restricted to children whose asthma remains uncon- 
trolled despite adequate inhaled corticosteroids. 
Ketotifen has not been found to be useful in estab- 
lished asthma but may still have a place in the 
management of atopic, pre-school children. Finally, 
importance of the drug delivery system was empha- 
sized along with the need to tailor this to the age and 
preference of the child and their family. 
The discussion on childhood asthma closed with a 
presentation on the factors influencing the prognosis 
of childhood asthma led by Peter Helms (University 
of Aberdeen, U.K.). The prevalence of asthma and 
wheezing illness in childhood is increasing although 
much of the increase appears to be for relatively mild, 
troublesome symptoms. Age-related factors have 
been shown to be very significant with an approxi- 
mate halving in the prevalence of wheezing illness 
from pre-school years to the early adolescent period. 
Much of this age-related effect can be explained 
by the maturation of the respiratory system and 
improved intrapulmonary airway support offered by 
a more stable chest wall during growth. The reversal 
of the male:female ratio over the same period is also 
of interest and may be partly explained by the 
different rates of maturation and of the respiratory 
system between the sexes. Studies in early infancy 
have suggested that intrauterine effects on pulmonary 
and, in particular, airway development may have a 
significant effect on the expression of wheezing illness 
in childhood and later life. Passive smoking remains 
the most significant factor so far identified. The 
inheritability of atopic disease is well known 
although the exact molecular mechanisms remain to 
be established. 
Long-term follow-up studies in stable populations 
have shown different prognoses for different types of 
wheezing illness and it is becoming clear that wheeze 
associated with viral infections has a much more 
benign, long-term prognosis than classical asthma 
associated with atopic disease and multiple provok- 
ing agents. Both of these broad types of wheezing 
illness appear to be inheritable while non-specific 
bronchial hyperresponsiveness to agents such as 
methacholine is strongly connected with virus- 
associated wheeze. In the 1950s and 1960s this 
syndrome was referred to as ‘wheezy bronchitis’ and 
although it has become unpopular to use this diag- 
nostic label, largely because of its association with 
under-treatment of wheezing illness in children, it 
appears that this syndrome is distinct from classical 
atopic asthma. Further molecular studies may delin- 
eate a different genetic origin for these different 
wheezing syndromes, while their different prognoses 
need to be taken into account when counselling 
affected individuals and their families. 
Adult Asthma - A Chronic Persistent Disease 
The second half of the meeting focused on adult 
asthma. Barry Kay (National Heart and Lung 
Institute, London) talked about the immunological 
basis of asthma. When atopic allergic individuals 
are exposed to a specific allergen, they experience 
an immediate early-response (which can serve as a 
model of seasonal allergic rhinitis or episodic asthma) 
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Fig. 2 Cell interactions and cytokines pathways in the pathophysiology of allergic mucosal inflammation. 
followed by a delayed-in-time, late-phase response 
(LPR) which has many of the characteristics of 
chronic rhinitis and asthma. It is widely accepted that 
the early asthmatic response (EAR) is the result of 
allergen interacting with IgE bound to high affinity 
receptors on mast cells, which in turn leads to an 
energy-dependent release of histamine and lipid 
mediators (leukotrienes, prostaglandins and platelet 
activating factor) (Fig. 2). Thus, mast cells located in 
the lumen, the epithelium and below the basement 
membrane of the upper and lower airways, elaborate 
granule-associated and newly-formed lipid mediators 
following activation and these mediators lead to 
smooth muscle contraction and mucosal oedema. 
Allergens are also recognized by local, specifically 
sensitized T cells (Fig. 2). An antigen must be pre- 
sented by accessory cells which in the airway might 
be dendritic cells, epithelial cells, local tissue macro- 
phages, endothelial cells or B lymphocytes. Present 
evidence suggests that in atopic allergy, there is a 
predominance of a specialized subset of CD4 T 
helper cells, termed Th2 cells, which preferentially 
elaborate interleukin-4 and interleukin-5 (IL-4, IL-5). 
Interleukin-4 is an essential co-factor for IgE produc- 
tion by B cells, whereas IL-5 (together with IL-3 and 
granulocyte/macrophage-colony stimulating factor, 
GM-CSF) plays a critical role in eosinophil matu- 
ration, activation and survival. T cellleosinophil 
interactions are believed to be critical in the patho- 
genesis of chronic allergic inflammation, particularly 
mucosal damage. Eosinophil precursors are CD34+ 
and, following maturation and activation, they 
express CD69 and secrete basic proteins from their 
crystalloid granules. These include the eosinophil cat- 
ionic protein (ECP) which stains with the monoclonal 
antibody, EG2. Eosinophils themselves are capable of 
transcribing and translating IL-3, IL-5 and GM-CSF 
which may feed back to act as local autocrine growth 
and survival factors. Damage to the bronchial 
mucosa in asthma is believed to be, at least in part, 
the result of eosinophil basic protein release and 
the generation of lipid mediators such as PAF and 
leukotriene C4 which cause vasodilatation, mucus 
hypersecretion and smooth muscle contraction. 
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subjects, binding of G-GR to GRE 
is impaired and reduced numbers of 
G-GR are translocated to the nucleus 
Fig. 3 The mechanisms of glucocorticosteroid resistance. G, glucocorticosteroid; GR, glucocorticosteroid receptor; 
HS P-90, 90 KDa heat shock protein; GRE, glucocorticosteroid response element. 
Peter Howarth (Southampton) presented work 
demonstrating the ability of the mast cell to synthe- 
size, store and release IL-4, IL-5, IL-6 and TNFa. 
These mediators can be released following binding of 
allergen to IgE on the surface of the mast cell. This 
has important implications for the role of the mast 
cell as a central cell in potentiating the chronic 
inflammatory changes in the asthmatic airway. 
The issue of corticosteroid-resistant bronchial 
asthma was addressed by Tak Lee (Guy’s and 
St. Thomas’s United Medical and Dental School, 
London). Corticosteroid-resistant asthma has been 
defined as asthma that responds to &agonists but 
shows less than 15% improvement in FEV, after 
a 15-day course of 40 mg of prednisolone. 
Corticosteroid-resistant asthma is associated with 
disease chronicity, a more frequent family history 
of asthma and impaired in vitro responsiveness of 
peripheral blood mononuclear cells to the suppres- 
sive effects of glucocorticosteroids. The Guy’s group 
has demonstrated that corticosteroid-resistant 
asthma is not due to altered bioavailability of orally 
administered prednisolone, to differences in ligand 
binding or to nuclear translocation of the glucocor- 
ticoid receptor. Instead, there appears to be impaired 
binding of a structurally normal glucocorticoid 
receptor to its glucocorticoid response element, as 
well as decreased numbers of nuclear translocated 
glucocorticoid receptors available for glucocorticoid 
response element binding in corticosteroid-resistant 
subjects (Fig. 3). Monocyte supernatants from 
corticosteroid-resistant asthmatic subjects have a 
neutrophil priming activity which is selectively 
resistant to in vitro suppression by glucocorticoids. 
Furthermore, in corticosteroid-resistant asthma 
using the classical intradermal tuberculin driven cell- 
mediated immune response, an in vivo defect in the 
responsiveness of mononuclear cells to glucocorti- 
coids has been shown, indicating that the phenom- 
enon of corticosteroid resistance is not organ specific. 
Asthma is often under-diagnosed in old age, and 
this issue was addressed by Lindsay Dow (University 
of Bristol, U.K.). Asthma in old age is usually taken 
to be non-allergic and this presumption has been 
based on the common finding of negative skin tests 
and low levels of total serum IgE. These observations 
have not allowed for the age-related decline in aller- 
gen skin reactivity and total IgE levels. When age- 
standardized IgE levels are used, levels are invariably 
raised in elderly asthmatics compared to population 
non-asthmatic controls. Asthma treatment in the 
elderly is similar to that of younger age groups, 
although a higher proportion require inhaler aids due 
to inability to co-ordinate actuation of the device 
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Table I New treatment strategies in asthma and allergic 
disease. These strategies are at different stages of develop- 
ment, for details see text 
New treatment strategies 
(1) Specific allergen immunotherapy 
- Modified allergen extracts 
- Peptide fragments 
(2) Control of IgE production 
- IL-4 receptor antagonists 
- Interferon gamma 
(3) Leukotriene receptor antagonists 
with inspiration. Greater attention to drug inter- 
action is required as many elderly patients take 
medication for other diseases and these may either 
exacerbate asthma or promote side-effects from 
bronchodilators or corticosteroids. 
The meeting closed with a presentation looking at 
new treatment strategies for asthma research from 
Anthony Frew (Southampton) (Table 1). 
Specific allergen immunotherapy has been widely 
used in Europe and North America but has fallen out 
of favour in the U.K. as a treatment for asthma, due 
to the risk of fatal adverse reactions which seem to be 
confined to patients with asthma as opposed to 
rhinitis. Novel forms of immunotherapy using modi- 
fied allergen extracts of peptide fragments offer the 
potential to allow effective desensitization without 
carrying the risk of serious adverse reactions. At 
present, these are undergoing field trials in allergic 
rhinitis and it is likely that their use will be extended 
to allergic asthma over the next few years. 
Alternative strategies to control IgE production 
have focused on the cytokines which regulate the 
production of IgE. IL-4 and IL-13 are required for 
the differentiation of B lymphocytes into IgE- 
secreting plasma cells. This process is inhibited by 
interferon gamma which is produced by a separate 
set of CD4+ T cells. In experimental models, deleting 
the IL-4 gene prevents mice from developing IgE 
responses and this has led a number of pharmaceuti- 
cal companies to consider the development of IL-4 
receptor antagonists as a possible strategy for con- 
trolling atopic allergy. Conversely, interferon gamma 
can inhibit the IL-4-producing T cells and has also 
been considered as a possible anti-asthma agent. 
Leukotriene receptor antagonists and synthesis 
inhibitors represent a promising new class of drug. 
They have been shown to be able to cause broncho- 
dilation in pre-constricted airways and to attenuate 
bronchoconstriction induced by a variety of stimuli 
including exercise, cold air and allergen. These agents 
are now undergoing clinical trials and have an imme- 
diate bronchodilator effect which is sustained over a 
period of 3 months and is associated with improve- 
ments in morning peak flow, asthma symptoms and a 
reduction in the requirement for additional bron- 
chodilator medication. More extensive trials are 
under way in more severe forms of asthma and in 
patients requiring long-term inhaled corticosteroids 
to assess their role as corticosteroid sparing agents. 
Other mediator antagonists, directed against platelet 
activating factor, thromboxane and prostaglandins, 
have not proved clinically useful. 
The meeting closed with a short address from 
Stephen Holgate (Southampton) who thanked the 
many speakers for their valuable contributions, and 
expressed the view that multidisciplinary workshops 
such as this were of considerable value as an 
educational tool in the health sciences. 
